Evidence map›Paper›PMID 28607917›Full record

ArticleStem cell investigation2017

Thrombotic microangiopathy associated with synthetic cannabinoid receptor agonists.

Michael Karass, Savneek Chugh, Gabriela Andries, Aleksandra Mamorska-Dyga, John C Nelson, Praveen N Chander

Open access · hybridAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Stem cell investigation, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.1field-weighted citation impact, top 53% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Michael KarassDivision of Internal Medicine, New York Medical College, Westchester Medical Center, Valhalla, NY 10595, USA.
Savneek ChughDivision of Nephrology, New York Medical College, Westchester Medical Center, Valhalla, NY 10595, USA.
Gabriela AndriesDivision of Internal Medicine, New York Medical College, Westchester Medical Center, Valhalla, NY 10595, USA.
Aleksandra Mamorska-DygaDivision of Hematology and Oncology, New York Medical College, Westchester Medical Center, Valhalla, NY 10595, USA.
John C NelsonDivision of Hematology and Oncology, New York Medical College, Westchester Medical Center, Valhalla, NY 10595, USA.
Praveen N ChanderDivision of Pathology, New York Medical College, Westchester Medical Center, Valhalla, NY 10595, USA.
New York Medical College · USWestchester Medical Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Marijuana is one of the most commonly used recreational drugs in the United States. As marijuana is illegal in the majority of countries, the use of readily available and unregulated synthetic cannabinoids (SCBs) has increased. Little is known about the potential adverse effects of SCBs especially in regards to their nephrotoxicity. Case reports of acute kidney injury (AKI) from acute tubular injury secondary to their use have been reported. However, the exact pathology, mechanism, and extent of renal injury remain unknown. We report the first case of biopsy proven thrombotic microangiopathy (TMA) associated with SCBs resulting in AKI. The patient suffered significant morbidity with loss of renal function eventually requiring renal replacement therapy.

Indexed as

acute kidney injury (AKI)synthetic cannabinoids (SCBs)synthetic marijuanaThrombotic microangiopathy (TMA)

Identifiers

PMID28607917
PMCPMC5460124
OpenAlexW2620006616

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.